img

Global Orphan Indication Drugs Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Orphan Indication Drugs Market Insights, Forecast to 2034

An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients.The classification of certain diseases, and the medicines that treat them, as "orphan" is a matter of public policy in many countries . Given the nature of the enormous economic resources required for medical research , these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance.In the United States and the European Union , orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive , few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research.
Global Orphan Indication Drugs market is expected to reach to US$ 641 million in 2024, with a positive growth of %, compared with US$ 633 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Orphan Indication Drugs industry is evaluated to reach US$ 734.7 million in 2029. The CAGR will be 2.3% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Orphan Indication Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Orphan Indication Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
Segment by Type
Biologics
Non-Biologics

Segment by Application


Hospital Pharmacy
Retail Pharmacy
Online Sales

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Orphan Indication Drugs plant distribution, commercial date of Orphan Indication Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Orphan Indication Drugs introduction, etc. Orphan Indication Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Orphan Indication Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Orphan Indication Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Orphan Indication Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Biologics
1.2.3 Non-Biologics
1.3 Market by Application
1.3.1 Global Orphan Indication Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Sales
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Orphan Indication Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Orphan Indication Drugs Revenue by Region
2.2.1 Global Orphan Indication Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Orphan Indication Drugs Revenue by Region (2018-2024)
2.2.3 Global Orphan Indication Drugs Revenue by Region (2024-2029)
2.2.4 Global Orphan Indication Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Orphan Indication Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Orphan Indication Drugs Sales by Region
2.4.1 Global Orphan Indication Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Orphan Indication Drugs Sales by Region (2018-2024)
2.4.3 Global Orphan Indication Drugs Sales by Region (2024-2029)
2.4.4 Global Orphan Indication Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Orphan Indication Drugs Sales by Manufacturers
3.1.1 Global Orphan Indication Drugs Sales by Manufacturers (2018-2024)
3.1.2 Global Orphan Indication Drugs Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Orphan Indication Drugs in 2022
3.2 Global Orphan Indication Drugs Revenue by Manufacturers
3.2.1 Global Orphan Indication Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Orphan Indication Drugs Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Orphan Indication Drugs Revenue in 2022
3.3 Global Key Players of Orphan Indication Drugs, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Orphan Indication Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Orphan Indication Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Orphan Indication Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Orphan Indication Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Orphan Indication Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Orphan Indication Drugs Sales by Type
4.1.1 Global Orphan Indication Drugs Historical Sales by Type (2018-2024)
4.1.2 Global Orphan Indication Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Orphan Indication Drugs Sales Market Share by Type (2018-2029)
4.2 Global Orphan Indication Drugs Revenue by Type
4.2.1 Global Orphan Indication Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Orphan Indication Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Orphan Indication Drugs Price by Type
4.3.1 Global Orphan Indication Drugs Price by Type (2018-2024)
4.3.2 Global Orphan Indication Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Orphan Indication Drugs Sales by Application
5.1.1 Global Orphan Indication Drugs Historical Sales by Application (2018-2024)
5.1.2 Global Orphan Indication Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Orphan Indication Drugs Sales Market Share by Application (2018-2029)
5.2 Global Orphan Indication Drugs Revenue by Application
5.2.1 Global Orphan Indication Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Orphan Indication Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Orphan Indication Drugs Price by Application
5.3.1 Global Orphan Indication Drugs Price by Application (2018-2024)
5.3.2 Global Orphan Indication Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Orphan Indication Drugs Market Size by Type
6.1.1 US & Canada Orphan Indication Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Orphan Indication Drugs Revenue by Type (2018-2029)
6.2 US & Canada Orphan Indication Drugs Market Size by Application
6.2.1 US & Canada Orphan Indication Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Orphan Indication Drugs Revenue by Application (2018-2029)
6.3 US & Canada Orphan Indication Drugs Market Size by Country
6.3.1 US & Canada Orphan Indication Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Orphan Indication Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Orphan Indication Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Orphan Indication Drugs Market Size by Type
7.1.1 Europe Orphan Indication Drugs Sales by Type (2018-2029)
7.1.2 Europe Orphan Indication Drugs Revenue by Type (2018-2029)
7.2 Europe Orphan Indication Drugs Market Size by Application
7.2.1 Europe Orphan Indication Drugs Sales by Application (2018-2029)
7.2.2 Europe Orphan Indication Drugs Revenue by Application (2018-2029)
7.3 Europe Orphan Indication Drugs Market Size by Country
7.3.1 Europe Orphan Indication Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Orphan Indication Drugs Sales by Country (2018-2029)
7.3.3 Europe Orphan Indication Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Orphan Indication Drugs Market Size
8.1.1 China Orphan Indication Drugs Sales (2018-2029)
8.1.2 China Orphan Indication Drugs Revenue (2018-2029)
8.2 China Orphan Indication Drugs Market Size by Application
8.2.1 China Orphan Indication Drugs Sales by Application (2018-2029)
8.2.2 China Orphan Indication Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Orphan Indication Drugs Market Size by Type
9.1.1 Asia Orphan Indication Drugs Sales by Type (2018-2029)
9.1.2 Asia Orphan Indication Drugs Revenue by Type (2018-2029)
9.2 Asia Orphan Indication Drugs Market Size by Application
9.2.1 Asia Orphan Indication Drugs Sales by Application (2018-2029)
9.2.2 Asia Orphan Indication Drugs Revenue by Application (2018-2029)
9.3 Asia Orphan Indication Drugs Sales by Region
9.3.1 Asia Orphan Indication Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Orphan Indication Drugs Revenue by Region (2018-2029)
9.3.3 Asia Orphan Indication Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Orphan Indication Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Orphan Indication Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Orphan Indication Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Orphan Indication Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Orphan Indication Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Orphan Indication Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Overview
11.1.3 Bristol-Myers Squibb Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Bristol-Myers Squibb Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Overview
11.2.3 Roche Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Roche Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Roche Recent Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Overview
11.3.3 Novartis Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Novartis Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Overview
11.4.3 Johnson & Johnson Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Johnson & Johnson Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Johnson & Johnson Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Pfizer Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Pfizer Recent Developments
11.6 Amgen
11.6.1 Amgen Company Information
11.6.2 Amgen Overview
11.6.3 Amgen Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Amgen Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Amgen Recent Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Sanofi Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Overview
11.8.3 AstraZeneca Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 AstraZeneca Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 AstraZeneca Recent Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Overview
11.9.3 Takeda Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Takeda Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Takeda Recent Developments
11.10 Vertex Pharmaceuticals
11.10.1 Vertex Pharmaceuticals Company Information
11.10.2 Vertex Pharmaceuticals Overview
11.10.3 Vertex Pharmaceuticals Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Vertex Pharmaceuticals Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Vertex Pharmaceuticals Recent Developments
11.11 AbbVie
11.11.1 AbbVie Company Information
11.11.2 AbbVie Overview
11.11.3 AbbVie Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 AbbVie Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AbbVie Recent Developments
11.12 Biogen
11.12.1 Biogen Company Information
11.12.2 Biogen Overview
11.12.3 Biogen Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Biogen Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Biogen Recent Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Overview
11.13.3 Eli Lilly Orphan Indication Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Eli Lilly Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Eli Lilly Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Orphan Indication Drugs Industry Chain Analysis
12.2 Orphan Indication Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Orphan Indication Drugs Production Mode & Process
12.4 Orphan Indication Drugs Sales and Marketing
12.4.1 Orphan Indication Drugs Sales Channels
12.4.2 Orphan Indication Drugs Distributors
12.5 Orphan Indication Drugs Customers
13 Market Dynamics
13.1 Orphan Indication Drugs Industry Trends
13.2 Orphan Indication Drugs Market Drivers
13.3 Orphan Indication Drugs Market Challenges
13.4 Orphan Indication Drugs Market Restraints
14 Key Findings in The Global Orphan Indication Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Orphan Indication Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Biologics
Table 3. Major Manufacturers of Non-Biologics
Table 4. Global Orphan Indication Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Orphan Indication Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Orphan Indication Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Orphan Indication Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Orphan Indication Drugs Revenue Market Share by Region (2018-2024)
Table 9. Global Orphan Indication Drugs Revenue Market Share by Region (2024-2029)
Table 10. Global Orphan Indication Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Orphan Indication Drugs Sales by Region (2018-2024) & (K Units)
Table 12. Global Orphan Indication Drugs Sales by Region (2024-2029) & (K Units)
Table 13. Global Orphan Indication Drugs Sales Market Share by Region (2018-2024)
Table 14. Global Orphan Indication Drugs Sales Market Share by Region (2024-2029)
Table 15. Global Orphan Indication Drugs Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Orphan Indication Drugs Sales Share by Manufacturers (2018-2024)
Table 17. Global Orphan Indication Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Orphan Indication Drugs Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Orphan Indication Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Orphan Indication Drugs Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Orphan Indication Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Orphan Indication Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Indication Drugs as of 2022)
Table 23. Global Key Manufacturers of Orphan Indication Drugs, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Orphan Indication Drugs, Product Offered and Application
Table 25. Global Key Manufacturers of Orphan Indication Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Orphan Indication Drugs Sales by Type (2018-2024) & (K Units)
Table 28. Global Orphan Indication Drugs Sales by Type (2024-2029) & (K Units)
Table 29. Global Orphan Indication Drugs Sales Share by Type (2018-2024)
Table 30. Global Orphan Indication Drugs Sales Share by Type (2024-2029)
Table 31. Global Orphan Indication Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Orphan Indication Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Orphan Indication Drugs Revenue Share by Type (2018-2024)
Table 34. Global Orphan Indication Drugs Revenue Share by Type (2024-2029)
Table 35. Orphan Indication Drugs Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Orphan Indication Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Orphan Indication Drugs Sales by Application (2018-2024) & (K Units)
Table 38. Global Orphan Indication Drugs Sales by Application (2024-2029) & (K Units)
Table 39. Global Orphan Indication Drugs Sales Share by Application (2018-2024)
Table 40. Global Orphan Indication Drugs Sales Share by Application (2024-2029)
Table 41. Global Orphan Indication Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Orphan Indication Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Orphan Indication Drugs Revenue Share by Application (2018-2024)
Table 44. Global Orphan Indication Drugs Revenue Share by Application (2024-2029)
Table 45. Orphan Indication Drugs Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Orphan Indication Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Orphan Indication Drugs Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Orphan Indication Drugs Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Orphan Indication Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Orphan Indication Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Orphan Indication Drugs Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Orphan Indication Drugs Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Orphan Indication Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Orphan Indication Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Orphan Indication Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Orphan Indication Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Orphan Indication Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Orphan Indication Drugs Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Orphan Indication Drugs Sales by Country (2024-2029) & (K Units)
Table 60. Europe Orphan Indication Drugs Sales by Type (2018-2024) & (K Units)
Table 61. Europe Orphan Indication Drugs Sales by Type (2024-2029) & (K Units)
Table 62. Europe Orphan Indication Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Orphan Indication Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Orphan Indication Drugs Sales by Application (2018-2024) & (K Units)
Table 65. Europe Orphan Indication Drugs Sales by Application (2024-2029) & (K Units)
Table 66. Europe Orphan Indication Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Orphan Indication Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Orphan Indication Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Orphan Indication Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Orphan Indication Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Orphan Indication Drugs Sales by Country (2018-2024) & (K Units)
Table 72. Europe Orphan Indication Drugs Sales by Country (2024-2029) & (K Units)
Table 73. China Orphan Indication Drugs Sales by Type (2018-2024) & (K Units)
Table 74. China Orphan Indication Drugs Sales by Type (2024-2029) & (K Units)
Table 75. China Orphan Indication Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Orphan Indication Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Orphan Indication Drugs Sales by Application (2018-2024) & (K Units)
Table 78. China Orphan Indication Drugs Sales by Application (2024-2029) & (K Units)
Table 79. China Orphan Indication Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Orphan Indication Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Orphan Indication Drugs Sales by Type (2018-2024) & (K Units)
Table 82. Asia Orphan Indication Drugs Sales by Type (2024-2029) & (K Units)
Table 83. Asia Orphan Indication Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Orphan Indication Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Orphan Indication Drugs Sales by Application (2018-2024) & (K Units)
Table 86. Asia Orphan Indication Drugs Sales by Application (2024-2029) & (K Units)
Table 87. Asia Orphan Indication Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Orphan Indication Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Orphan Indication Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Orphan Indication Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Orphan Indication Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Orphan Indication Drugs Sales by Region (2018-2024) & (K Units)
Table 93. Asia Orphan Indication Drugs Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Orphan Indication Drugs Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Orphan Indication Drugs Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Orphan Indication Drugs Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Orphan Indication Drugs Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Orphan Indication Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Orphan Indication Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Orphan Indication Drugs Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Orphan Indication Drugs Sales by Country (2024-2029) & (K Units)
Table 107. Bristol-Myers Squibb Company Information
Table 108. Bristol-Myers Squibb Description and Major Businesses
Table 109. Bristol-Myers Squibb Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Bristol-Myers Squibb Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Bristol-Myers Squibb Recent Developments
Table 112. Roche Company Information
Table 113. Roche Description and Major Businesses
Table 114. Roche Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Roche Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Roche Recent Developments
Table 117. Novartis Company Information
Table 118. Novartis Description and Major Businesses
Table 119. Novartis Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Novartis Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Novartis Recent Developments
Table 122. Johnson & Johnson Company Information
Table 123. Johnson & Johnson Description and Major Businesses
Table 124. Johnson & Johnson Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Johnson & Johnson Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Johnson & Johnson Recent Developments
Table 127. Pfizer Company Information
Table 128. Pfizer Description and Major Businesses
Table 129. Pfizer Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Pfizer Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Pfizer Recent Developments
Table 132. Amgen Company Information
Table 133. Amgen Description and Major Businesses
Table 134. Amgen Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Amgen Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Amgen Recent Developments
Table 137. Sanofi Company Information
Table 138. Sanofi Description and Major Businesses
Table 139. Sanofi Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Sanofi Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Sanofi Recent Developments
Table 142. AstraZeneca Company Information
Table 143. AstraZeneca Description and Major Businesses
Table 144. AstraZeneca Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. AstraZeneca Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. AstraZeneca Recent Developments
Table 147. Takeda Company Information
Table 148. Takeda Description and Major Businesses
Table 149. Takeda Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Takeda Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Takeda Recent Developments
Table 152. Vertex Pharmaceuticals Company Information
Table 153. Vertex Pharmaceuticals Description and Major Businesses
Table 154. Vertex Pharmaceuticals Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Vertex Pharmaceuticals Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Vertex Pharmaceuticals Recent Developments
Table 157. AbbVie Company Information
Table 158. AbbVie Description and Major Businesses
Table 159. AbbVie Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. AbbVie Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. AbbVie Recent Developments
Table 162. Biogen Company Information
Table 163. Biogen Description and Major Businesses
Table 164. Biogen Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Biogen Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Biogen Recent Developments
Table 167. Eli Lilly Company Information
Table 168. Eli Lilly Description and Major Businesses
Table 169. Eli Lilly Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Eli Lilly Orphan Indication Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Eli Lilly Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Orphan Indication Drugs Distributors List
Table 175. Orphan Indication Drugs Customers List
Table 176. Orphan Indication Drugs Market Trends
Table 177. Orphan Indication Drugs Market Drivers
Table 178. Orphan Indication Drugs Market Challenges
Table 179. Orphan Indication Drugs Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Orphan Indication Drugs Product Picture
Figure 2. Global Orphan Indication Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Orphan Indication Drugs Market Share by Type in 2022 & 2029
Figure 4. Biologics Product Picture
Figure 5. Non-Biologics Product Picture
Figure 6. Global Orphan Indication Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Orphan Indication Drugs Market Share by Application in 2022 & 2029
Figure 8. Hospital Pharmacy
Figure 9. Retail Pharmacy
Figure 10. Online Sales
Figure 11. Orphan Indication Drugs Report Years Considered
Figure 12. Global Orphan Indication Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Orphan Indication Drugs Revenue 2018-2029 (US$ Million)
Figure 14. Global Orphan Indication Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 15. Global Orphan Indication Drugs Revenue Market Share by Region (2018-2029)
Figure 16. Global Orphan Indication Drugs Sales 2018-2029 ((K Units)
Figure 17. Global Orphan Indication Drugs Sales Market Share by Region (2018-2029)
Figure 18. US & Canada Orphan Indication Drugs Sales YoY (2018-2029) & (K Units)
Figure 19. US & Canada Orphan Indication Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 20. Europe Orphan Indication Drugs Sales YoY (2018-2029) & (K Units)
Figure 21. Europe Orphan Indication Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 22. China Orphan Indication Drugs Sales YoY (2018-2029) & (K Units)
Figure 23. China Orphan Indication Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Asia (excluding China) Orphan Indication Drugs Sales YoY (2018-2029) & (K Units)
Figure 25. Asia (excluding China) Orphan Indication Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Orphan Indication Drugs Sales YoY (2018-2029) & (K Units)
Figure 27. Middle East, Africa and Latin America Orphan Indication Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 28. The Orphan Indication Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 29. The Top 5 and 10 Largest Manufacturers of Orphan Indication Drugs in the World: Market Share by Orphan Indication Drugs Revenue in 2022
Figure 30. Global Orphan Indication Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Orphan Indication Drugs Sales Market Share by Type (2018-2029)
Figure 32. Global Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
Figure 33. Global Orphan Indication Drugs Sales Market Share by Application (2018-2029)
Figure 34. Global Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
Figure 35. US & Canada Orphan Indication Drugs Sales Market Share by Type (2018-2029)
Figure 36. US & Canada Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
Figure 37. US & Canada Orphan Indication Drugs Sales Market Share by Application (2018-2029)
Figure 38. US & Canada Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Orphan Indication Drugs Revenue Share by Country (2018-2029)
Figure 40. US & Canada Orphan Indication Drugs Sales Share by Country (2018-2029)
Figure 41. U.S. Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 42. Canada Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Orphan Indication Drugs Sales Market Share by Type (2018-2029)
Figure 44. Europe Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
Figure 45. Europe Orphan Indication Drugs Sales Market Share by Application (2018-2029)
Figure 46. Europe Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
Figure 47. Europe Orphan Indication Drugs Revenue Share by Country (2018-2029)
Figure 48. Europe Orphan Indication Drugs Sales Share by Country (2018-2029)
Figure 49. Germany Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 50. France Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 51. U.K. Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 54. China Orphan Indication Drugs Sales Market Share by Type (2018-2029)
Figure 55. China Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
Figure 56. China Orphan Indication Drugs Sales Market Share by Application (2018-2029)
Figure 57. China Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
Figure 58. Asia Orphan Indication Drugs Sales Market Share by Type (2018-2029)
Figure 59. Asia Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
Figure 60. Asia Orphan Indication Drugs Sales Market Share by Application (2018-2029)
Figure 61. Asia Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
Figure 62. Asia Orphan Indication Drugs Revenue Share by Region (2018-2029)
Figure 63. Asia Orphan Indication Drugs Sales Share by Region (2018-2029)
Figure 64. Japan Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 66. China Taiwan Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 67. Southeast Asia Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 68. India Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Orphan Indication Drugs Sales Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Orphan Indication Drugs Revenue Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Orphan Indication Drugs Sales Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Orphan Indication Drugs Revenue Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Orphan Indication Drugs Revenue Share by Country (2018-2029)
Figure 74. Middle East, Africa and Latin America Orphan Indication Drugs Sales Share by Country (2018-2029)
Figure 75. Brazil Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 76. Mexico Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 77. Turkey Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 78. Israel Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 79. GCC Countries Orphan Indication Drugs Revenue (2018-2029) & (US$ Million)
Figure 80. Orphan Indication Drugs Value Chain
Figure 81. Orphan Indication Drugs Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries